Mapi Pharma Appoints Charles Makin To lead North America Health Economics & Outcomes Research Team

Mapi Pharma Appoints Charles Makin To lead North America Health Economics & Outcomes Research Team

YARDLEY, Pa., Oct. 30, 2014 /PRNewswire/ -- Mapi, a global leader in Real-World Evidence, Health Economics & Outcomes Research (HEOR), Market Access, Epidemiology and Patient-Centered Research solutions, strengthens its North American team with the appointment of Charles Makin as Vice President, HEOR and Strategic Market Access.

In his new role, Mr. Makin will expand Mapi's existing Patient-Centered services and support our clients' increasing demand for HEOR and market access solutions. He will be responsible for the day-to-day operations of Mapi's Boston, Toronto and Yardley based HEOR and Strategic Market Access teams.

"Charles' appointment expands Mapi's Health Economics and Outcomes Research presence in North America, provides additional local expertise to Mapi's current client base and creates opportunities for continued growth," commented James Karis, Mapi Group's CEO.

Charles brings over a decade of experience in Health Economics and Outcomes Research acquired through positions at Humana, Wellpoint and OptumInsight. Mr. Makin joins Mapi from IMS Health, where he has held positions of increasing responsibility culminating as the head of Observational Outcomes Research for the Americas and Principal of Health Economics & Outcomes Research.

Among his thought leadership contributions, Mr. Makin has authored over 50 peer-reviewed articles/abstracts; presented at conferences of the American Managed Care Pharmacy, American Academy of Neurology, American Thoracic Society, European Congress of Rheumatology, World Ophthalmology Conference, World Congress on ADHD and ISPOR. He has served as Principal Investigator on a large number of global retrospective database studies, registries, patient/physician surveys, systematic literature reviews and economic models across all major therapeutic areas; and has developed and implemented drug value and effectiveness roadmaps for most of the top 20 pharmaceutical companies to positively impact market access.

To learn more about Mapi's Patient-Centered Research capabilities visit www.mapigroup.com.

About Mapi:

Mapi is the global leader in Patient-Centered research services including Real World Evidence, Post-Marketing, Registries, Linguistic Validation, Health Economics, Strategic Market Access and through the Mapi Research Trust; the largest library of Clinical Outcome Assessments.

With over 40 years of experience in administering and developing insight from Real-World Evidence. Mapi supports Life-Science companies, Government Funded Health agencies, Health Technology Assessment (HTA) providers, Accountable Care Organizations (ACOs) and Regulatory bodies in gathering and evaluating data on Therapies, Pharmaceuticals, Biologicals, and Medical devices. Visit http://www.mapigroup.com for more information. Press contact: Elan Josielewski, 1-859-338-7211, [email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.